In 2023, Jason Gardner earned $4.37M in total compensation at Dianthus Therapeutics, including $571.46K salary, $690.00K bonus and $3.09M in stock. Currently holds stock worth $1.49M. Has donated $1.32M in stock to charitable causes. Led Dianthus Therapeutics as CEO for 1 years.
Compensation History
Annual executive compensation data for Jason Gardner, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$4.37M
Salary
$571.46K
Bonus
$690.00K
Other
$16.70K
Salary
$571.46KBoard Justification
The compensation committee believes that executive compensation should be strongly linked to Company performance and the creation of long-term value for stockholders, with a significant portion of total compensation being performance-based.
Bonus
$690.00KBoard Justification
The payouts for our CEO and other NEOs were at or above target, as a result of both individual and company performance as measured by the Senior Executive Cash Incentive Bonus Plan (the “Bonus Plan”).
Other Compensation
$16.70KBoard Justification
Includes 401(k) matches and other stipends for parking, commute, connectivity, and cell phones.
Restricted Stock
Board Justification
Shares of RSUs that vested in 2023, reflecting the achievement of performance metrics and continued service.
Performance Metrics
Year-Over-Year Revenue Growth, Gross Profit, Adjusted EBITDA.
Jason Gardner
Founder and Ex-CEO of Dianthus Therapeutics
Education
Ph.D. in Molecular Biology from the University of Cambridge
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
Born
January 1, 1973 - 52 years ago
CEO of Dianthus Therapeutics for
1 year 1 month (Jan 2022 - Feb 2023)
Previous Experience
Co-founder and CEO of Magenta Therapeutics
Other Dianthus Therapeutics CEOs
Holdings
Track Jason Gardner's stock holdings and portfolio value over time.
Charitable Transactions
283,000 shares
MQ
Recent Charitable Transactions
183,000 shares
MQ
Mar 10, 2025
Charity
100,000 shares
MQ
Aug 19, 2022
Charity
Insider Trading
Jason Gardner's recent stock transactions, purchases, and sales filed with the SEC.
183,000 shares
MQ
Mar 10, 2025
Charity
100,000 shares
MQ
Aug 19, 2022
Charity
Rivals
Compare Jason Gardner with competitor CEOs and industry peers.